Comparative Pharmacology
Head-to-head clinical analysis: PAPA DEINE 3 versus ROXICET 5 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAPA DEINE 3 versus ROXICET 5 500.
PAPA-DEINE #3 vs ROXICET 5/500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen produces analgesia and antipyresis via central COX-2 inhibition and activation of descending serotonergic pathways. Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits ascending pain pathways and alters pain perception.
Oxycodone is a full opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and producing analgesic and antipyretic effects.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 12 tablets in 24 hours. Each tablet contains acetaminophen 300 mg, codeine phosphate 30 mg.
1-2 tablets (5-10 mg oxycodone / 325-650 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 12 tablets per day (60 mg oxycodone / 6000 mg acetaminophen) in 24 hours.
None Documented
None Documented
Codeine: 2.5-3 hours; Acetaminophen: 2-3 hours; Morphine (active metabolite): 2-3 hours. In hepatic impairment, codeine half-life may extend to 4-6 hours.
Oxycodone: 3-5 hours (immediate-release); Acetaminophen: 2-3 hours. In hepatic impairment, oxycodone half-life prolonged (up to 12-15 hours).
Primarily renal (90% as glucuronide conjugates, 10% as morphine, codeine, and norcodeine). Biliary/fecal elimination accounts for <5%.
Oxycodone: primarily hepatic metabolism to noroxycodone, oxymorphone, and conjugates; renal elimination of metabolites (about 60-87% as unchanged and metabolites), fecal < 10%. Acetaminophen: renal elimination of conjugates (90-100%), <5% unchanged.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination